Filing Details
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:CNSP
CNS Pharmaceuticals, Inc. (CNSP) Files Quarterly Report for Q0
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
At publication ·
What changed
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- CNS Pharmaceuticals, Inc. filed its quarterly report (Form 10-Q) with the SEC on August 12, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $5.01 with a market capitalization of $4.4 million as of the filing date.
- The 10-Q filing includes updated risk factors and changes in business conditions since the last annual report, though specific revenue figures and financial metrics are not disclosed in this summary.
Market Context
CNS Pharmaceuticals, Inc.'s stock currently trades at $5.01 with a market capitalization of $4.4M.
The 10-Q provides CNS Pharmaceuticals, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for CNS Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CNSP Stock Page
Frequently Asked Questions
Where can I read CNSP's SEC filings?
Browse all filings on our CNSP SEC filings page.
What types of SEC filings does CNS Pharmaceuticals, Inc. file?
Public companies like CNS Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.